Research Article

Clinical Characteristics and Outcomes of Acute Ischemic Stroke in Patients with Type 2 Diabetes: A Single-Center, Retrospective Study in Southern China

Minrui Chen,1 Weiliang Luo,2 Jiming Li,2 Kaiyi Cao,2 Xiaohui Li,2 Huihong Huang,2 and Yan He2

1Department of the First Clinical Medicine, Guangdong Medical University, Zhanjiang 524023, Guangdong, China
2Department of Neurology, Huizhou Hospital Affiliated to Guangdong Medical University Huizhou Municipal Central Hospital, Huizhou 516001, Guangdong, China

Correspondence should be addressed to Weiliang Luo; lwl306@126.com

Received 18 January 2021; Accepted 18 May 2021; Published 14 June 2021

Academic Editor: Alexander Schreiber

Copyright © 2021 Minrui Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To explore the associations between type 2 diabetes mellitus (DM) and stroke by evaluating the clinical risk factors, characteristics, and outcomes of acute ischemic stroke (AIS) patients with and without type 2 DM. Methods. A total of 1,156 AIS patients (including 410 with type 2 DM (AIS-DM group) and 746 without type 2 DM (AIS-NDM group)) were included. Patients’ demographics, auxiliary examinations, clinical manifestations, and treatment outcomes were recorded and analyzed. Results. Among the included AIS patients, 35.46% had type 2 DM. The AIS-DM group had less males (59.76% versus 70.64%), less smokers (33.90% versus 41.96%), more patients with hypertension (72.93% versus 63.94%; \( p \leq 0.002 \)), higher triglyceride levels (42.93% versus 25.08%; \( p \leq 0.01 \)), and lower total cholesterol (147.06 mg/dl versus 175.31 mg/dl) than the AIS-NDM group. The proportion of patients with large artery atherosclerosis (LAA) in the AIS-DM group was lower (77.56% versus 85.92%; \( p < 0.05 \)) than that in the AIS-NDM group, and the proportion of patients with small arterial occlusions (SAO) in the AIS-DM group was higher (27.07% versus 13.67%; \( p < 0.05 \)) than that in the AIS-NDM group. The mean National Institutes of Health Stroke Scale (NIHSS) score at admission in the AIS-DM group was lower than that in the AIS-NDM group (4.39 versus 5.00; \( p \leq 0.008 \)), but there was no significant difference in the NIHSS score or the modified Rankin Scale score between the two groups at discharge. A total of 85 AIS patients underwent intravenous thrombolysis treatment with recombinant tissue plasminogen activator (rtPA). The door-to-needle time (DNT) did not differ significantly between the groups (49.39 ± 30.40 min versus 44.25 ± 15.24 min; \( p = 0.433 \)). In addition, there were no significant differences in the baseline NIHSS score, 7-day NIHSS score, and mRS score at discharge between the groups. After intravenous thrombolysis with rtPA, the AIS-NDM group had better recovery (44.30% versus 29.20%; \( p = 0.017 \)) and a higher ratio of good treatment outcome at discharge (65.60% versus 54.20%; \( p = 0.762 \)). Conclusions. Type 2 DM is associated with AIS and its risk factors, such as dyslipidemia and hypertension. Patients in the AIS-DM group had less LAA and smaller arterial occlusions, and DM could exacerbate the short-term clinical outcomes in AIS patients.

1. Introduction

Diabetes mellitus (DM) is a common chronic metabolic disorder characterized by a high blood glucose level, which has prevalence of 8.8% in the general population worldwide [1]. In 2019, approximately 463 million people had DM globally [2]. In the last 20 years, the prevalence of DM has increased rapidly in China, with an annual growth rate of approximately 0.72%, ranking it first among Asian countries and much higher than that in the United States [2]. In China, type 2 DM, which is known as adult-onset diabetes, accounts for approximately 95% of all DM cases [3]. In addition, DM increases the risk of stroke 2–5 times, and >90% of DM-induced strokes are due to cerebral infarction [4, 5].

Stroke is an acute cerebrovascular disease, which includes three subtypes: ischemic stroke, hemorrhagic stroke,
Patients were classified as having type 2 DM if they self-reported type 2 DM, had a DM medical record, and used hypoglycemic medications (e.g., insulin or sulfonylureas). If the patient reported that they had type 2 DM but had not used (or only irregularly used) hypoglycemic medication or the patient did not know whether they had type 2 DM or not, the diagnosis was made based on the following criteria: (1) glycated hemoglobin (HbA1c) ≥6.5%, (2) fasting plasma glucose (FPG) ≥126 mg/dL, (3) 2-hour blood glucose ≥200 mg/dL on oral glucose tolerance test, or (4) random blood glucose (RPG) ≥200 mg/dL with typical symptoms of hyperglycemia or hyperglycemic crisis [21].

Patient baseline information that included gender, age, blood pressure, HbA1c, and fasting blood triglycerides (TG)/total cholesterol(TC)/low-density lipoprotein cholesterol (LDL-C) was recorded upon admission. The assessment of baseline risk factors included a history of cerebral infarction, hypertension, atrial fibrillation, smoking, alcohol consumption, coronary heart disease, and heart failure. Serum TG/TC/LDL-C levels were measured by enzymatic measurement (Cobas c702 analyzer, Roche Diagnostics GmbH, Germany). Serum HbA1c levels were measured using high-performance liquid chromatography (Variant II analyzer, Bio-Rad Diagnostics GmbH, USA).

For the definitions of hypertension, atrial fibrillation, smoking, and alcohol consumption, the definitions used in the stroke’s epidemiological risk factor survey in mainland China since 2013 were adopted [17]. Hypertension was defined as self-reported high blood pressure (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or both), use of antihypertensive medications, or recorded hypertension in the medical record. Atrial fibrillation was defined by a previous medical history of atrial fibrillation or a new clinical diagnosis based on an electrocardiogram. Coronary heart disease was defined by a previous medical history of myocardial infarction or angina pectoris or a new clinical diagnosis based on the cardiovascular events that were confirmed by a cardiologist during hospitalization. Heart failure was defined by a previous medical history of heart failure or a new clinical diagnosis based on clinical symptoms. Dyslipidemia was defined as abnormal blood lipids detected in a blood test during hospitalization, use of blood lipid-lowering medication, or recorded abnormal blood lipid levels in the medical record. The abnormal cut-off values of lipid profile were diagnosed based on the Guidelines for the Prevention and Treatment of Dyslipidemia in Adults in China: (1) TC ≥200 mg/dL, (2) TG ≥150 mg/dL, or (3) LDL-C ≥130 mg/dL [22, 23]. Alcohol consumption referred to alcohol intake ≥1 time/week at any time. Smoking was defined as ≥1 instance of tobacco use/day.

Stroke-related neurologic deficits and impairments were measured by the National Institutes of Health Stroke Scale (NIHSS) [24]. Clinical outcomes of patients were assessed by the modified Rankin Scale (mRS) [25].
2.2. Statistical Analysis. SPSS 26.0 software was used for data analysis. The count data were expressed as frequency/percentage, and the Chi-squared test was used to compare the data between both groups. Measurement data were expressed as mean ± standard deviation (SD). A Student's t-test was used for data with a normal distribution, and a nonparametric test was used for data without normal distribution. An independent-sample t-test was used for the comparison of independent samples. A p value ≤ 0.05 was considered statistically significant.

3. Results

A total of 1,156 AIS patients including 410 patients (35.46%) with type 2 DM (AIS-DM group) and 746 patients (64.53%) without type 2 DM (AIS-NDM group) were enrolled in this study. The risk factors of both groups were compared, and several differences were observed (Table 1). The AIS-DM group had fewer males (59.76% versus 70.64%) and fewer smokers (33.90% versus 41.96%). There was no significant difference in those who received ≥1 lipid-lowering drug for ≥3 months before admission between the AIS-DM group and AIS-NDM group (14.88% versus 17.96%; p = 0.190). Lower TC (147.06 mg/dL versus 175.31 mg/dL) was found in the AIS-DM group (all p < 0.05). The AIS-DM group showed significantly higher TG (42.93% versus 25.08%; p ≤ 0.01). In addition, the AIS-DM group had a higher percentage of patients with hypertension (72.93% versus 63.94%; p = 0.002).

The percentage of patients with LAA in the AIS-DM group was lower than that in the AIS-NDM group (77.56% versus 85.92%; p < 0.05). However, the percentage of patients with infarction with small arterial occlusion (SAO) in the AIS-DM group was higher than that in the AIS-NDM group (27.07% versus 13.67%; p < 0.002). The AIS-DM group showed significantly higher NIHSS score (4.39 versus 3.00; p = 0.008), but no significant differences in the NIHSS score and mRS score were observed between both groups at discharge (Table 2).

Among the patients included in this study, 85 (7.3%) AIS patients (24 in the AIS-DM group and 61 in the AIS-NDM group) underwent rtPA intravenous thrombolysis treatment. There was no significant difference in door-to-needle time (DNT) between the two groups (44.25 ± 15.24 min versus 49.39 ± 30.40 min; p = 0.433). In addition, there were no significant differences in the baseline NIHSS score, 7-day NIHSS score, and mRS score at discharge between the two groups (Tables 3 and 4). After intravenous thrombolysis with rtPA, the AIS-NDM group had better recovery (e.g., 7-day NIHSS score decreased by 4 points; 44.30% versus 29.20%; p = 0.017; Table 4) and a higher percentage of patients with a favorable outcome by using mRS score at discharge (65.60% versus 54.20%; p = 0.762; Table 5).

4. Discussion

The clinical characteristics and treatment outcomes of 1,156 AIS patients from southern China were examined in this study. In total, 35.46% of AIS patients had type 2 DM, and the AIS-DM group had a significantly higher rate of hypertension and abnormal TG compared with the AIS-NDM group. In addition, the AIS-DM group had a higher percentage of patients with SAO cerebral infarction and poorer treatment outcomes (regardless of thrombolysis or non-thrombolysis treatment) at discharge, compared with the AIS-NDM group.

Although many studies demonstrated associations between stroke (including AIS) and DM [13–18], the results of this study could offer a valuable contribution to the management of AIS-DM patients for the following reasons. First, the prevalence rates of stroke or type 2 DM or both in China are different from those in many other countries [3, 26]. For instance, China reported a higher incidence of stroke patients compared to other countries globally, and stroke is the most common cause of death in China [26]. In addition, China has the largest population with diabetes (mainly type 2 DM) within a single country [4]. Therefore, this study reflected the real-world conditions for type 2 DM and AIS in China. Second, the prevalence rates of stroke and type 2 DM show significant geographic variations throughout China [3–5, 9, 12]; therefore, this study reflected the real-world situation for DM and AIS in southern China, which is a developed region in China. Third, some studies were carried out many years ago and might not represent the current situation in China, in particular in southern China, which has experienced very rapid economic growth during the last two decades. Fourth, the outcomes for stroke patients in China appear to be comparable with those in other high-income countries, and one reason might be that Chinese stroke patients tend to be younger [26]. Therefore, knowledge on the associations between DM and AIS might improve the country or region-specific prevention and management of AIS.

In this study, 35.46% of AIS patients had type 2 DM, and this percentage agreed with the data in some previous studies [16, 18, 19, 27]. However, the results of this study did not agree with some other reports. Recently, Guangdong Province (in which Huizhou is located) and Shandong Province published the results of epidemiological investigations into stroke [28–30]. AIS-DM patients in Guangdong accounted for 20.0% of all stroke patients and this percentage was 12.0% in Shandong. However, the incidence of stroke in Shandong (northern China) was approximately two times that in Guangdong (southern China). This was because the prevalence of stroke is related to other risk factors, such as hypertension, atrial fibrillation, smoking, drinking, air pollution, and elevated blood lipid levels [26]. In addition, the difference in the prevalence of stroke might be related to the differences between the traditional northern diet (a high intake of refined cereal products and salt due to salted vegetables) and the traditional southern diet (high intake of rice, fruit, and vegetables and a low intake of salt) in China [26].

In this study, the mean prevalence of DM in stroke patients which was reported in Huizhou was higher than that in Guangdong, which indicated that, within the same province, the prevalence of DM, stroke, and AIS-DM might be related to other factors, such as socioeconomic status and...
Table 1: Clinical risk factors of study participants.

| Clinical risk factors                  | NDM group (n = 746) | DM group (n = 410) | Total (n = 1156) | p value  |
|----------------------------------------|---------------------|-------------------|-----------------|---------|
| Gender (male) (n, %)                   | 527 (70.64%)        | 245 (59.76%)      | 772 (66.78%)    | ≤0.010* |
| Age (mean ± SD; years)                 | 64.85 ± 12.71       | 64.03 ± 10.48     | 64.56 ± 11.97   | 0.164   |
| History of AIS (n, %)                  | 165 (22.12%)        | 78 (19.02%)       | 243 (21.02%)    | 0.228   |
| Smoking (n, %)                         | 313 (41.96%)        | 139 (33.90%)      | 452 (39.10%)    | 0.008*  |
| Drinking (n, %)                        | 105 (14.13%)        | 56 (13.69%)       | 161 (13.93%)    | 0.929   |
| Hypertension (n, %)                    | 477 (63.94%)        | 299 (72.93%)      | 776 (67.13%)    | 0.002*  |
| Atrial fibrillation (n, %)             | 36 (4.83%)          | 25 (6.10%)        | 61 (5.28%)      | 0.409   |
| Coronary heart disease (n, %)          | 50 (6.70%)          | 39 (9.51%)        | 89 (7.70%)      | 0.106   |
| Heart failure (n, %)                   | 34 (4.56%)          | 10 (2.44%)        | 44 (3.81%)      | 0.078   |
| TG (≥150 mg/dL) (n, %)                 | 187 (25.08%)        | 176 (42.93%)      | 363 (31.40%)    | ≤0.010* |
| TC (≥200 mg/dL) (n, %)                 | 209 (28.02%)        | 103 (25.12%)      | 312 (26.99%)    | 0.300   |
| TG (mean ± SD; mg/dL)                  | 148.85 ± 518.22     | 183.40 ± 202.01   | 160.37 ± 433.25 | ≤0.010* |
| TC (mean ± SD; mg/dL)                  | 175.31 ± 49.03      | 147.06 ± 81.08    | 165.25 ± 63.70  | ≤0.010* |
| LDL-C (≥130 mg/dL) (n, %)              | 313 (41.96%)        | 160 (39.02%)      | 473 (40.92%)    | 0.349   |
| LDL-C (mean ± SD; mg/dL)               | 114.55 ± 53.83      | 101.01 ± 63.24    | 109.52 ± 57.66  | 0.005*  |
| Statins/fenofibrate use (n, %)         | 134 (17.96%)        | 61 (14.88%)       | 195 (16.87%)    | 0.190   |

* p < 0.05. SD: standard deviation; NDM: no diabetes mellitus; AIS: acute ischemic stroke; TG: triglycerides; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol.

Table 2: Classification of etiology and prognosis at discharge of the participants.

| Clinical characteristics | NDM group (n = 746) | DM group (n = 410) | Total (n = 1156) | p value  |
|--------------------------|---------------------|-------------------|-----------------|---------|
| SAO (n, %)               | 102 (13.67%)        | 111 (27.07%)      | 213 (18.43%)    | ≤0.010* |
| LAA (n, %)               | 641 (85.92%)        | 318 (77.56%)      | 959 (82.96%)    | ≤0.010* |
| Mean NIHSS (on admission)| 5.00                | 4.39              | 4.78            | 0.008*  |
| Mean NIHSS (at discharge)| 3.46                | 3.44              | 3.46            | 0.161   |
| Favorable prognosis (mRS score: 0–2) (n, %) at discharge | 527 (70.64%) | 281 (68.54%) | 808 (69.90%) | 0.462 |

* p < 0.05. NDM: no diabetes mellitus; SAO: small-artery occlusion; LAA: large-artery atherosclerosis; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale.

Table 3: Comparison of outcomes of rtPA intravenous thrombolysis of both groups.

| Group | n | Baseline NIHSS score (on admission) | 7-day NIHSS score | mRS score (at discharge) | DNT |
|-------|---|------------------------------------|------------------|--------------------------|-----|
| NDM   | 61| 9.13 ± 6.36                        | 5.98 ± 8.49      | 1.98 ± 1.63              | 49.39 ± 30.40 |
| DM    | 24| 6.63 ± 4.29                        | 5.88 ± 6.09      | 2.50 ± 1.53              | 44.25 ± 15.24 |
| t     |   | 1.776                               | 0.570            | ~1.338                   | 0.789 |
| p value |   | 0.079                               | 0.955            | 0.185                    | 0.433 |

* p < 0.05. rtPA: recombinant tissue plasminogen activator; SD: standard deviation; NDM: no diabetes mellitus; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; DNT: door-to-needle time.

Table 4: Comparison of 7-day NIHSS scores after rtPA intravenous thrombolysis of both groups.

| Group | n | 7-day NIHSS score decreased by >4 points | 7-day NIHSS score decreased by <4 points | Effective rate |
|-------|---|------------------------------------------|------------------------------------------|----------------|
| NDM   | 61| 27                                       | 34                                       | 0.443          |
| DM    | 24| 7                                        | 17                                       | 0.292          |
| X²    |   | ~                                       | ~                                        | 5.324          |
| p value |   | ~                                       | ~                                        | 0.017*         |

* p < 0.05. rtPA: recombinant tissue plasminogen activator; NIHSS: National Institutes of Health Stroke Scale; NDM: no diabetes mellitus.

Table 5: Comparison of mRS scores at discharge after rtPA thrombolytic therapy of both groups.

| Group | n | mRS score: 0–2 (favorable prognosis) | mRS score: 3–6 | Proportion (mRS score: 0–2) |
|-------|---|--------------------------------------|----------------|---------------------------|
| NDM   | 61| 40                                    | 21             | 0.656                     |
| DM    | 24| 13                                    | 8              | 0.542                     |
| X²    |   | ~                                    | ~              | 0.092                     |
| p value |   | ~                                    | ~              | 0.762                     |

* p < 0.05. mRS: modified Rankin Scale; rtPA: recombinant tissue plasminogen activator; NDM: no diabetes mellitus.
levels and the manipulation of lipid metabolism in type 2 DM patients might be beneficial for the prevention and treatment of AIS, especially in China, where dyslipidemia is relatively common (34%) and often poorly controlled [26].

Lacunar infarct, the most frequent subtype of AIS, results from the occlusion of small arteries that supply the deep structures of the brain [42]. Overall, >90% of stroke patients with DM have cerebral infarction (mostly lacunar infarction), and DM is regarded as a major modifiable risk factor for lacunar infarct [43]. In this study, the percentage of patients with SAO in the AIS-DM group was significantly higher than that in the AIS-NDM group (27.07% versus 13.67%), which agreed with previous reports [43, 44]. One explanation could be that atherosclerosis (caused by type 2 DM) at the ostium of the perforating arteries of the brain might lead to lacunar infarct [43]. The NIHSS score at admission was lower in the AIS-DM group than in the AIS-NDM group. However, there were no differences in NIHSS scores, treatment outcomes (mRS score: 0–2), and mortality between the two groups at discharge, which agrees with some previous studies [43, 45].

Intravenous thrombolysis with rtPA is a specific and effective treatment for AIS. In this study, 85 AIS patients underwent rtPA intravenous thrombolysis. There was no statistical difference in the DNT time between both groups. However, the treatment was less effective in the AIS-DM group, because there were fewer patients with a decreased NIHSS score (≥4) after 7 days of rtPA treatment or with a mRS score of 0–2 at discharge. The worst outcome of rtPA intravenous thrombolysis in AIS-DM patients agreed with the results of previous reports [46, 47].

There are some limitations to this study. First, because this study was a single-center, retrospective study and the subject size was limited, selection bias was inevitable. Second, because the effectiveness of treatment was observed during hospitalization and at discharge, the long-term outcomes of the AIS patients were not evaluated. Third, for patients with type 2 DM, the duration and types of treatment or medications were not recorded, which might affect the evaluation of the data.

In conclusion, this study provided significant knowledge on the association between AIS and type 2 DM in the population of southern China. These results could facilitate the country or region-specific prevention and management of AIS by promoting reductions in modifiable risk factors.

Data Availability

The datasets used, analyzed, or both during this study are available from the corresponding author upon reasonable request.

Ethical Approval

The study was approved by the Ethics Committee of Huizhou City Central Municipal Hospital 【KYLL2020107】. All procedures performed in the studies that involved human participants complied with the ethical standards of the institutional or national research committee or both and with the 1964 Helsinki Declaration and its later amendments or
comparable ethical standards. Data were handled in a manner that did not reveal the identity of any patients or control subjects; therefore, formal consent (written or oral) for individuals was not required.

Conflicts of Interest

All authors declare that they have no conflicts of interest.

Authors’ Contributions

Weiliang Luo and Minrui Chen designed and managed the study. Minrui Chen, Jiming Li, Kaiyi Cao, Xiaohui Li, Huihong Huang, and Yan He enrolled patients and collected study data. Xiaohui Li and Jiming Li performed the statistical analysis. Minrui Chen wrote the manuscript draft. Weiliang Luo revised the paper and had primary responsibility for the final content. All authors read and approved the final manuscript.

References

[1] A. M. Schmidt, “Highlighting diabetes mellitus: the epidemic continues,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 38, no. 1, pp. e1-e8, 2018.
[2] P. Saudelli, I. Petersohn, P. Salpea et al., “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition,” Diabetes Research and Clinical Practice, vol. 157, Article ID 107843, 2019.
[3] American Diabetes Association, “Classification and diagnosis of diabetes,” Diabetes Care, vol. 38, pp. S8–S16, 2015.
[4] K. Jamrozik, R. J. Broadhurst, S. Forbes, G. J. Hankey, and C. S. Anderson, “Predictors of death and vascular events in the elderly: the Perth community stroke study,” Stroke, vol. 31, no. 4, pp. 863–868, 2000.
[5] T. M. E. Davis, “Risk factors for stroke in type 2 diabetes mellitus,” Archives of Internal Medicine, vol. 159, no. 10, p. 1097, 1999.
[6] R. L. Sacco, S. E. Kasner, J. P. Broderick et al., “An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American heart association/ American heart association stroke association,” Stroke, vol. 44, no. 7, pp. 2064–2089, 2013.
[7] C. Chugh, “Acute ischemic stroke: management approach,” Indian Journal of Critical Care Medicine, vol. 23, pp. S140–S146, 2019.
[8] GBD 2015 Mortality and Causes of Death Collaborators, “Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015,” Lancet, vol. 386, no. 10053, pp. 1459–1544, 2016.
[9] X. Ru, W. Wang, H. Sun et al., “Geographical difference, rural-urban transition and trend in stroke prevalence in China: findings from a national epidemiological survey of stroke in China,” Scientific Reports, vol. 9, no. 1, Article ID 17330, 2019.
[10] A. K. Boehme, C. Esenwa, and M. S. V. Elkind, “Stroke risk factors, genetics, and prevention,” Circulation Research, vol. 120, no. 3, pp. 472–495, 2017.
[11] M. T. Altemimi and A. R. Hashim, “Acute stroke in diabetes mellitus: a prospective observational study evaluating the course and short-term outcome in basrah, southern Iraq,” Cureus, vol. 11, no. 10, Article ID e6017, 2019.
[12] S. Hu, B. Cui, M. Mlynash, X. Zhang, K. M. Mehta, and M. G. Lansberg, “Stroke epidemiology and stroke policies in China from 1980 to 2017: a systematic review and meta-analysis,” International Journal of Stroke, vol. 15, no. 1, pp. 18–28, 2020.
[13] A. M. Schmidt, “Diabetes mellitus and cardiovascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 39, no. 4, pp. 558–568, 2019.
[14] S. A. E. Peters, R. R. Huxley, and M. Woodward, “Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes,” The Lancet, vol. 383, no. 9933, pp. 1973–1980, 2014.
[15] Y. Pan, Y. Wang, H. Li, H. Y. Gaisano, Y. Wang, and Y. He, “Association of diabetes and prognosis of minor stroke and its subtypes: a prospective observational study,” Plos One, vol. 11, no. 4, Article ID e015317, 2016.
[16] R. Chen, B. Ovbiagie, and W. Feng, “Diabetes and stroke: epidemiology, pathophysiology, pharmaceuticals and outcomes,” The American Journal of the Medical Sciences, vol. 351, no. 4, pp. 380–386, 2016.
[17] W. Wang, B. Jiang, H. Sun et al., “Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480,687 adults,” Circulation, vol. 135, no. 8, pp. 759–771, 2017.
[18] Q. Jia, X. Zhao, C. Wang et al., “Diabetes and poor outcomes within 6 months after acute ischemic stroke,” Stroke, vol. 42, no. 10, pp. 2758–2762, 2011.
[19] Q. Jia, H. Zheng, X. Zhao et al., “Abnormal glucose regulation in patients with acute stroke across China,” Stroke, vol. 43, no. 3, pp. 650–657, 2012.
[20] H. P. Adams, B. H. Bendixen, I. J. Kappelle et al., “Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment,” Stroke, vol. 24, no. 1, pp. 35–41, 1993.
[21] American Diabetes Association, “2. classification and diagnosis of diabetes: standards of medical care in diabetes-2019,” Diabetes care, vol. 42, pp. S13–S28, 2019.
[22] China JCoT, “Guidelines for the prevention and treatment of dyslipidemia in adults in China (2016 revision),” Zhonghua Quan Ke Yi Shi Za Zhi, vol. 16, pp. 15–35, 2017.
[23] China JCoT, “Guidelines for the prevention and treatment of dyslipidemia in adults in China,” Zhonghua XinXueGuOngZaZhi, vol. 35, pp. 390–419, 2007.
[24] T. Brott, H. P. Adams, C. P. Olinger et al., “Measurements of acute cerebral infarction: a clinical examination scale,” Stroke, vol. 20, no. 7, pp. 864–870, 1989.
[25] W. N. Kernan, B. Ovbiagle, H. R. Black et al., “Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart association/American stroke association,” Stroke, vol. 45, no. 7, pp. 2160–2236, 2014.
[26] S. Wu, B. Wu, M. Liu et al., “Stroke in China: advances and challenges in epidemiology, prevention, and management,” Lancet Neurol, vol. 18, no. 4, pp. 394–405, 2019.
[27] J. B. Echouffo-Tcheugui, H. Xu, R. A. Matsouaka et al., “Diabetes and long-term outcomes of ischaemic stroke: findings from get with the guidelines-stroke,” European Heart Journal, vol. 39, no. 25, pp. 2376–2386, 2018.
[28] L. J. Jianle, W. Ying, F. Huiyun et al., “Epidemiology of stroke in Guangdong province, China,” Chinese Journal of Nervous and Mental Diseases, vol. 46, no. 1, pp. 1–7, 2020.
[29] Z. Shengnian, S. Xiaohan, Z. Xueying et al., “Epidemiology of stroke and its risk factors in Shandong province, China,” *Chinese Journal of Neurology*, vol. 52, no. 9, pp. 716–723, 2019.

[30] M. Zhou, H. Wang, X. Zeng et al., “Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global burden of disease study 2017,” *The Lancet*, vol. 394, no. 10204, pp. 1145–1158, 2019.

[31] V. L. Feigin, G. A. Roth, M. Naghavi et al., “Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the global burden of disease study 2013,” *The Lancet Neurology*, vol. 15, no. 9, pp. 913–924, 2016.

[32] G. Colussi, A. Da Porto, and A. Cavarape, “Hypertension and type 2 diabetes: lights and shadows about causality,” *Journal of Human Hypertension*, vol. 34, no. 2, pp. 91–93, 2020.

[33] Y. Huang, L. Gao, X. Xie, and S. C. Tan, “Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control,” *Population Health Metrics*, vol. 12, no. 1, p. 28, 2014.

[34] Z. Wang, Y. Ping, H. Dayi, and Z. Shuiping, “Re-analysis of dyslipidemia in Chinese cross-sectional survey according to Chinese guidelines for the prevention and treatment of dyslipidemia in adults (2016 revision),” *Chinese Journal of Cardiovascular Medicine*, vol. 25, no. 1, pp. 55–61, 2020.

[35] J. D. Schofield, Y. Liu, P. Rao-Balakrishna, R. A. Malik, and H. Soran, “Diabetes dyslipidemia,” *Diabetes Therapy*, vol. 7, no. 2, pp. 203–219, 2016.

[36] C. Cheng, Y. Liu, X. Sun et al., “Dose-response association between the triglycerides: high-density lipoprotein cholesterol ratio and type 2 diabetes mellitus risk: the rural Chinese cohort study and meta-analysis,” *Journal of Diabetes*, vol. 11, no. 3, pp. 183–192, 2019.

[37] J. Gainey, B. Blum, B. Bowie et al., “Stroke and dyslipidemia: clinical risk factors in the telestroke versus non-telestroke,” *Lipids in Health and Disease*, vol. 17, no. 1, p. 226, 2018.

[38] S. Yaghi and M. S. V. Elkind, “Lipids and cerebrovascular disease: research and practice,” *Stroke*, vol. 46, no. 11, pp. 3322–3328, 2015.

[39] E. Shahar, L. E. Chambless, W. D. Rosamond et al., “Plasma lipid profile and incident ischemic stroke: the atherosclerosis risk in communities (ARIC) study,” *Stroke*, vol. 34, no. 3, pp. 623–631, 2003.

[40] J. J. Freiberg, A. Tybjaerg-Hansen, J. S. Jensen, and B. G. Nordestgaard, “Nonfasting triglycerides and risk of ischemic stroke in the general population,” *Jama*, vol. 300, no. 18, pp. 2142–2152, 2008.

[41] S. Bansal, J. E. Buring, N. Rifai, S. Mora, F. M. Sacks, and P. M. Ridker, “Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women,” *Jama*, vol. 298, no. 3, pp. 309–316, 2007.

[42] R. W. Regenhardt, A. S. Das, E. H. Lo, and L. R. Caplan, “Advances in understanding the pathophysiology of lacunar stroke: A review,” *JAMA Neurology*, vol. 75, no. 10, pp. 1273–1281, 2018.

[43] S. Palacio, L. A. McClure, O. R. Benavente, C. Bazan, P. Pergola, and R. G. Hart, “Lacunar strokes in patients with diabetes mellitus: risk factors, infarct location, and prognosis: the secondary prevention of small subcortical strokes study,” *Stroke*, vol. 45, no. 9, pp. 2689–2694, 2014.

[44] L.-M. Wei, Y.-Q. Zhu, Y.-Q. Bao et al., “Atherosclerosis in intracranial or extracranial vessels in diabetic patients and the association with stroke subtype,” *Quantitative Imaging in Medicine and Surgery*, vol. 9, no. 6, pp. 960–967, 2019.

[45] S.-E. Megherbi, C. Milan, D. Minier et al., “Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke,” *Stroke*, vol. 34, no. 3, pp. 688–694, 2003.

[46] N. D. Kruyt, G. J. Biessels, J. H. Devries, and Y. B. Roos, “Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management,” *Nature Reviews Neurology*, vol. 6, no. 3, pp. 145–155, 2010.

[47] G. Tsivgoulis, A. H. Katsanos, D. Mavridis et al., “Association of baseline hyperglycemia with outcomes of patients with and without diabetes with acute ischemic stroke treated with intravenous thrombolysis: a propensity score-matched analysis from the SITS-ISTR registry,” *Diabetes*, vol. 68, no. 9, pp. 1861–1869, 2019.